Tumors with low-to-moderate MGMT immunoexpression showed a significantly higher rate of invasiveness (p = 0.002) and recurrence (p < 0.001) but no significance for higher MIB-1 (p > 0.05), higher rate of atypia (WHO, p > 0.05; Trouillas Classification: 1a = 3/26; 1b = 9/17; 2a = 17/25; 2b = 4/8) or higher rate of positive MSH6 immunoexpression (p > 0.05) was found compared to tumours with high MGMT (>50%) immunoexpression (Table 3). The gene discussed is MGMT; the disease is neoplasm.